Business
Neurothera Labs Signs Non-Binding Term Sheet to Acquire Majority Stake in a Quantum Algorithm Bio Data Analysis Company
(TheNewswire) December 2, 2025 – TheNewswire - Vancouver, British Columbia, Canada...
About this update from Neurothera Labs Inc.
[{"type":"text","content":"Neurothera Labs Signs Non-Binding Term Sheet to Acquire Majority Stake in a Quantum Algorithm Bio Data Analysis Company\n\n\n (TheNewswire)\n \n\n\n\n\n\n\n\n December 2, 2025 –\n \n TheNewswire -\n \n Vancouver,\nBritish Columbia, Canada -  Neurothera Labs Inc. (TSXV: NTLX) (\n \n “\n \n\n Neurothera\n \n ” or the\n \n “\n \n\n Company\n \n ”), a clinical-stage\nbiotech company and a majority-owned subsidiary of SciSparc Ltd.\n(Nasdaq: SPRC), today announced that it has entered into a non-binding\nterm sheet (the “\n \n Term\nSheet\n \n ”) with a pioneering quantum computing bio data company\nfocused on quantum-enabled clinical analytics (the “\n \n Target Company\n \n \"). Under the\nterms of the Term Sheet, Neurothera will acquire a 55% equity interest\nin the Target Company, calculated on a post transaction fully diluted\nbasis, from certain selling shareholders of the Target Company (the\n“\n \n Selling Shareholders\n \n ”),\nin consideration for the issuance to the Selling Shareholders of that\namount of common shares in the capital of Neurothera (“Common\nShares”) as is equal to 40% of the Common Shares, calculated on a\nnon-diluted post transaction basis (the “\n \n Acquisition\n \n ”).\n \n\n By harnessing the principles of quantum computing, bio data can be\nstored, manipulated, and analyzed far more efficiently than existing\ntechnologies, potentially revolutionizing the field through\naccelerated processing and enhanced insights. This innovative approach\nis based on key quantum phenomena such as superposition, entanglement,\nand inherent parallelism to deliver faster computations and superior\nmachine learning performance. In turn, it strives to redefine clinical\ntrials via quantum intelligence, seamlessly integrating quantum\ncomputing with bioinformatics and clinical data science to potentially\nunlock precision and speed in medical research and development.\n \n\n Closing of the Acquisition remains subject to the completion of due\ndiligence, negotiation and execution of definitive agreements, receipt\nof all required corporate and regulatory approvals, including that of\nthe TSX Venture Exchange, and other customary closing conditions.\nThere can be no assurance that any definitive agreement will be\nentered i...